Trial Profile
An Open-label, Randomized, Parallel-group Trial to Evaluate the Pharmacokinetics of Two Formulations of LY03003 After a Single Intramuscular Injection Administered to Patients With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Nov 2018
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Luye Pharma Group
- 06 Nov 2018 Status changed from recruiting to completed.
- 20 Jul 2018 New trial record